Sanofi Receives FDA Approval of Soliqua(TM) 100/33, for the Treatment of Adults with Type 2 Diabetes

Sanofi Receives FDA Approval of Soliqua(TM) 100/33, for the Treatment of Adults with Type 2 Diabetes

November 21, 2016 – Sanofi announced today that the U.S. Food and Drug Administration approved once-daily Soliqua 100/33 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide*. Soliqua 100/33 is the combination of LantusA and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients.